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and	 hormonal	 medication	 use	 were	 evaluated	 with	 self‐designed	 questionnaires.	
Response	 of	 the	 largest	 HCA	 was	 evaluated	 according	 to	 Response	 Evaluation	
Criteria	in	Solid	Tumours	(RECISTv1.1).	Cox	regression	was	performed	for	analysis	of	
factors	influencing	HCA	regression.











K E Y W O R D S
hepatocellular	adenoma,	oral	contraceptive	pill,	regression,	treatment	algorithm
2  |     HARING et Al.
1  | INTRODUC TION
Hepatocellular	 adenomas	 (HCA)	 are	 rare,	 hormone‐driven	 benign	
liver	tumours.	They	mainly	develop	in	young	women	in	their	repro‐
ductive	age.	While	HCA	have	an	incidence	rate	around	one	per	mil‐
lion	 per	 year	 in	 the	 general	 population,	 long‐term	 (>2	years)	 users	
of	oral	contraceptive	pills	(OCP)	have	30‐	to	40‐fold	increased	risk	




Hepatocellular	 adenomas	 can	 be	 classified	 into	 subtypes.	
Inflammatory	HCA	(I‐HCA)	comprise	40%	to	55%	and	are	most	com‐
mon	in	patients	with	obesity	and/or	metabolic	syndrome.	They	are	








through	 immunohistochemical	 analysis	 of	 glutamine	 synthetase.	
Finally,	 there	 are	 unclassified	 HCA	 and	 sonic	 hedgehog	 activated	
HCA,	each	accounting	for	5%	to	10%	of	HCA.
Sex	 hormones	 or	 androgens	 stimulate	 both	 de novo	 forma‐
tion	as	well	as	growth	of	HCA.2,10	Hence,	women	using	OCP	and	
those	using	 anabolic	 steroids	 are	particularly	 at	 risk	of	HCA	de‐
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2  | MATERIAL S AND METHODS
2.1 | Study design and population
All	 female	HCA	 patients	 treated	 at	 the	 University	Medical	 Center	
Groningen	(UMCG)	between	2005	and	2018	were	included.	After	ob‐
taining	informed	consent,	patients	were	subjected	to	a	self‐designed	
questionnaire	 regarding	 biometrical	 information,	 comorbidities	 and	
exact	 intake	of	all	hormonal	medication	such	as	OCP.	Analysis	was	
performed	on	female	HCA	patients	with	a	history	of	oestrogen	con‐
taining	OCP	 intake	and	consecutive	 imaging	available.	Baseline	 im‐
aging	was	defined	as	imaging	within	6	months	prior	to	or	after	OCP	
cessation.	The	minimum	amount	of	follow‐up	was	at	least	one	scan	
obtained	by	either	magnetic	 resonance	 imaging	 (MRI)	or	computed	
tomography	 (CT),	 6	months	 after	OCP	 cessation	 or	 6	months	 after	








with	 the	 Response	 Evaluation	 Criteria	 in	 Solid	 Tumours	 (RECIST)	


















are:	 ‘complete	 response’	 defined	 by	 disappearance	 of	 all	 lesions,	
‘partial	 response’	defined	by	at	 least	30%	regression,	 ‘progressive	








2.3 | Data collection and definitions
Relevant	information	was	obtained	from	electronic	patient	files	and	
a	 self‐designed	 questionnaire.	Obesity	was	 defined	 by	 body	mass	





Continuous	 variables	 were	 described	 using	 the	 median	 with	 in‐
terquartile	 range,	whereas	nominal	 and	ordinal	 variables	were	de‐
scribed	 using	 totals,	 frequencies	 and	 percentages.	 Normality	 was	






considered	 statistically	 significant.	Cox	proportional	 hazard	model	
was	 used	 to	 determine	 factors	 that	 are	 independently	 associated	
with	>30%	regression	 in	HCA	diameter.	Patients	were	categorized	
into	<	or	≥	median	 values.	Categories	were	made	 (1)	 on	 less	 than	
and	(2)	equal	to	or	larger	than	the	median.	Variables	with	a	P	<	0.10	
at	 univariate	 analysis	 were	 included	 in	 the	 multivariate	 analysis.	
The	statistical	 analyses	were	performed	using	 IBM	SPSS	statistics	
version	 23.0	 (SPSS	 Inc,	 Chicago,	 IL).	 Figures	were	 generated	with	
GraphPad	Prism	version	5.0	(GraphPad	Software,	La	Jolla,	CA).
3  | RESULTS














intake	 of	OCP	 at	 a	median	 age	 of	 15	 (14‐17)	 years	 and	 stopped	
after	 15	 (10‐24)	 years	 of	 intake.	 Two‐thirds	 of	 patients	 took	 an	
oestrogen/progesterone	combination	preparation	containing	less	
than	 50	µg	 oestrogen,	 3.8%	 took	 a	 preparation	with	 50	µg,	 and	






performed	 to	 analyse	 the	 correlation	 of	 the	 age	 of	 commence‐
ment	 and	 total	 duration	 of	 OCP	 intake	 to	 HCA	 size	 at	 diagno‐
sis.	 Earlier	 commencement	 was	 not	 associated	 with	 larger	 HCA	
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(rs(11)	=	0.085,	P	=	0.53),	 and	 neither	was	 total	 duration	 of	OCP	
intake	(rs(11)	=	0.050,	P	=	0.71)	(Table	1).
3.2 | HCA response to OCP cessation
At	 the	 end	 of	 follow‐up,	 four	HCA	 demonstrated	 a	 complete	 re‐
sponse	(5.1%),	29	HCA	(37.2%)	showed	a	partial	response,	44	HCA	
(56.4%)	 remained	 stable,	 and	 one	 HCA	 (1.3%)	 showed	 progres‐






progressed	 to	 a	≥	50	mm	 diameter.	 Thirty‐nine	 HCA	 were	 larger	
than	50	mm	at	diagnosis,	median	size	at	diagnosis	86	(60‐110)	mm	
and	final	diameter	55	(41‐81)	mm	after	1	(0.4‐2.9)	year.	In	this	sub‐





HCA size at 
diagnosis <50 mm, n = 39
≥50‐<100 mm, 
n = 26 ≥100 mm, n = 13 P‐value
Female 39	(100%) 26	(100%) 15	(100%) —
Age	at	diagnosis,	y 31.0	(26.0‐40.0) 36.5	(29‐44) 31.0	(24.5‐41.0) 0.21a 
Body	mass	index,	
kg/m2
27.0	(22.9‐33.4) 32.0	(25.7‐35.3) 30.6	(28.1‐34.3) 0.08a 
Oral	contraceptive	use
Age	at	start,	y 15.0	(14.0‐16.0) 16.0	(14.0‐18.0) 15.0	(14.0‐17.0) 0.62b 
Age	at	
cessation,	y
31.0	(27.0‐40.0) 33.0	(29.0‐41.0) 29.5	(25.0‐39.3) 0.47a 
Duration	of	
intake,	y




TA B L E  1  Baseline	characteristics
















dian	of	8.5	 (5.8‐14.1)	months	 after	diagnosis	 (Table	3).	 The	major‐
ity	of	cases	was	 treated	 through	either	segment	 resection	 (n = 10)	
or	 (extended)	 hemihepatectomy	 (n = 5).	 Open	 thermal	 ablation	 of	
an	additional	lesion	was	performed	in	three	patients	with	segment	
resections.	 Three	 cases	 were	 treated	 through	 minimally	 invasive	
percutaneous	 treatment	 –	 radiofrequency	 or	 microwave	 ablation	
or	 transarterial	 embolization.	 Almost	 two‐thirds	 of	 ≥50	mm	 HCA	












for	mesh	 repair.	Another	 patient	 experienced	biliary	 leakage	 after	
a	 left	 hemihepatectomy	 requiring	 a	 reoperation	 with	 a	 roux‐en‐Y	
hepaticojejunostomy.
3.5 | Factors associated with HCA regression
Rate	of	HCA	regression	was	analyzed	(Figure	3A).	HCA	size	at	base‐
line	was	significantly	associate	with	rate	of	regression	(Figure	3B).	
Duration	 of	 intake	 was	 not	 associated	 with	 rate	 of	 regression	
though	(Figure	3C).	Increased	BMI	was	associated	with	larger	HCA	
diameter	 at	 diagnosis.	 Analysis	 using	 a	 Cox	 proportional	 hazard	
model,	however,	did	not	demonstrate	a	 relation	with	 the	 rate	of	



































TA B L E  3  Patients	with	invasive	treatment
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HCA	regression	(Figure	3D).	Duration	of	OCP	intake	was	not	re‐
lated	to	the	rate	of	HCA	regression.	HCA	diameter	at	baseline	was	
significantly	 related	 to	 the	 rate	 of	HCA	 regression.	Next,	 a	 Cox	
proportional	 hazard	 model	 was	 performed	 for	 univariate	 analy‐






















sion	 rate	 and	 the	 timing	 of	HCA	 resection.	 Klompenhouwer	 et	 al	
stated	that	15%	of	HCA	in	their	cohort	showed	regression	to	50	mm	
or	 smaller	 after	6	months.	This	 increased	 to	25%	of	patients	 after	
1 year.18	 Also,	 they	 observed	 that	 larger	HCA	 often	 require	more	
than	6	months	to	regress	to	a	diameter	<50	mm.18	Their	sample	size	







Apart	 from	 including	 few	 other	 HCA	 subtypes	 than	 I‐HCA,	
our	study	has	potential	weaknesses.	We	cannot	rule	out	any	re‐
sidual	 bias,	which	 is	 inherent	 to	 the	 retrospective	design	of	 our	
study.	We	were	unable	 to	perform	extensive	subanalyses	 in	 the	
group	with	 regression	 to	<50	mm	 in	 size	because	of	our	 sample	
size	(n	=	49	at	baseline).	Our	study	focused	on	the	relative	change	
of	HCA	diameter.	 In	 the	clinical	 setting,	however,	absolute	HCA	
size	 (≥50	mm)	 remains	 crucial	 for	 treatment.	Hence,	we	 are	 not	


























































HCA,	 Hepatocellular	 Adenoma;	 b‐Cat,	 b‐Catenin;	 GS,	 glutamine	 syn‐
thetase.	For	HCA	subtype	explanation,	see	introduction.








esized	 that	 the	 oestrogen	 (and	 general	 androgen)	 sensitivity	 of	










Weight,	kg/m2 <30	vs	≥30 1.273 0.630‐2.574 0.50
Start	of	OCP	use <15	vs	≥15 1.102 0.491‐2.475 0.81
Duration	of	OCP	
use
<15	vs	≥15 0.880 0.401‐1.935 0.75
Age	of	HCA	
diagnosis






<50	vs	≥100 8.394 3.260‐21.612 <0.001
HCA,	hepatocellular	adenoma;	OCP,	oral	contraceptive	pill.	Bold	values	indicate	statistical	significance.
TA B L E  5  Univariate	analysis	of	HCA	
regression	to	≥30%	of	baseline	size	by	the	
Cox	proportional	hazards	model
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HCA	is	because	of	an	increased	expression	of	all	androgen	recep‐
tors,	 and	oestrogen	 receptors	 in	 specific.	Unfortunately,	 studies	
which	 identified,	 characterized	 and	 quantified	 these	 receptors,	
only	analysed	small	patient	series	(<20	cases).	In	addition,	none	of	
the	authors	performed	any	 subtype	analysis	 as	 these	have	been	
identified	since	2008.19,20	This	might	have	resulted	in	unwittingly	
staining	 a	mix	 of	HCA	 subtypes.	 Future	 research	will	 determine	
the	 definite	 role	 of	 oestrogen	 receptors	 in	 the	 HCA	 (subtype)	
response.
We	 observed	 that	 HCA	 diameter	 at	 presentation	 was	 larger	
in	 obese	 patients.	While	 one	 could	 argue	 this	 could	 be	 explained	
through	a	reduction	of	auto‐sensation	of	any	liver	masses	in	obese	
patients	compared	to	 lean	patients,	age	of	diagnosis	did	not	differ	
between	 the	 two	 groups.	 A	 possible	 mechanism	 is	 the	 additional	









tion	 is	 of	 importance	 as	 current	 guidelines	 do	 not	 take	 baseline	






may	 potentially	 prevent	 surgical	 interventions	 in	 some	 patients.	
Although	complication	rates	are	low,	the	two	major	surgical	com‐
plications	 we	 observed	 underscore	 the	 potential	 risk	 associated	
with	surgery.
In	conclusion,	we	found	that	the	98%	of	HCA	remain	either	sta‐
ble	 or	 show	 regression	 after	OCP	 cessation.	 Large	HCA	 showed	
faster	regression	than	small	HCA,	but	this	required	a	 longer	time	
than	the	currently	advised	6‐month	period.	No	HCA‐induced	com‐
plications	 were	 observed	 during	 follow‐up.	 A	 conservative	 ap‐
proach	 could	 lead	 to	HCA	 regression	 below	50	mm	 and	 thereby	
potentially	 prevent	 unnecessary	 hepatic	 surgery	 in	 a	majority	 of	
patients.
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